TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Editorial
Keywords: non-adherence, .
This article has 0 comments
Tackling the adherence crisis
Two recent reports are flagging up a problem of near crisis proportions that is leading to unnecessary disease progression, reduced quality of life or even death, and costs an estimated $150– $300 billion annually in the US alone. The US National Council on Patient Information and Education is talking in terms of “America’s other drug problem”; the WHO is calling it “a worldwide problem of striking magnitude”. Both refer to a growing crisis of ‘non-adherence’ – patients not sticking to their prescriptions – which has so far been overlooked as a serious public health issue, despite the high human and financial cost.
» Kathy Redmond
To read the complete article please click on the pdf icon
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.